SINGAPORE, May 27, 2018 /PRNewswire/ — Lion TCR Pte Ltd, a clinical stage biotech pioneering T cell therapy against viral- related cancer, announced today they have raised US$ 20 million in its Series A financing round. The money raised is led primarily by undisclosed existing investors…



Source link